XPO Inc <XPO.N>: Raymond James cuts target price to $225 from $233
XPO•Related News

Veralto schedules Q2 2026 earnings call and webcast
VLTO•

Enlivex says FDA grants RMAT designation for Allocetra in age-related knee osteoarthritis
ENLV•

MKS schedules Q2 2026 earnings release, conference call
MKSI•

Intel invests EUR 5 billion to expand chip manufacturing at Ireland Leixlip campus
INTC•

Sana Biotechnology plans IND filing, targets Phase 1/2 start this year for SC451 type 1 diabetes therapy
SANA•